The purpose of this legislation, known as the Most Favored Patient Act of 2026, is to require the Center for Medicare and Medicaid Innovation to test a new pricing model for prescription drugs. This model is called the Most Favored Nations Pricing Model, which aims to ensure that the prices paid for certain drugs in the United States are not higher than those paid in other countries. The key provisions of this legislation include the requirement that drug manufacturers provide access to the most-favored-nation price for their covered drugs.